力勁(00558.HK)與文燦簽戰略合作股價漲11% 無懼收市後剔出MSCI香港微型指數組合
將於今天收市後遭剔除MSCI香港微型指數組合的力勁科技(00558.HK)與文燦股份(603348.SH)就超大型壓鑄件技術等方面的合作簽訂戰略合作協議。
力勁科技股價三連漲,尤其是今早逆市高見12.78元,再度逼近本月初所創上市高位13.36元,現造12.62元,逆漲11%,成交增至445萬股,涉資5,485萬元。
匯豐研究本月中旬首予力勁「買入」評級看14元。報告指,力勁在壓鑄機方面有壟斷地位,目前Tesla正使用於Model Y底盤的工序上,力勁去年底成為Tesla達6,000噸壓強壓鑄機的獨家供應商。同時,預期力勁於行業領先優勢可維持兩至三年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.